Literature DB >> 27121920

A review of 111 anaesthetic patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Sze Ying Thong1, Claramae Shulyn Chia2, Oriana Ng1, Grace Tan2, Ee Teng Ong1, Khee Chee Soo2, Melissa Teo2.   

Abstract

INTRODUCTION: Cytoreductive surgery (CRS) along with hyperthermic intraperitoneal chemotherapy (HIPEC) is the treatment of choice for selected patients with peritoneal carcinomatosis, a previously lethal condition with dismal survival rates.
METHODS: We reviewed CRS and HIPEC procedures performed at our centre from January 1997 to December 2012, focusing on perioperative events and anaesthetic implications.
RESULTS: In total, 111 patients underwent 113 procedures. Mean age of the patients was 51.7 (range 14-74) years and 84.1% were women. Mean duration of surgery was 9 hours 10 minutes ± 2 hours 56 minutes. Most tumours were ovarian or colorectal in origin, and the mean peritoneal cancer index (PCI) score was 14.3 ± 8.9. Mean estimated blood loss was 1,481 ± 1,064 mL. Mean total intravenous fluids and blood products administered was 8,498 ± 3,941 mL. Postoperatively, 79.5% of the patients needed intensive care, as 75.2% of the 113 procedures required interval extubation. Patients with lower PCI scores were more likely to be extubated immediately after surgery (p < 0.05). 80.0% of patients had coagulopathy postoperatively, and this was associated with longer HIPEC duration (p < 0.05). Median lengths of intensive care unit and hospital stays were two days and 14 days, respectively. Longer duration of surgery significantly correlated with longer hospitalisation. Prolonged hospitalisation was due to nosocomial pneumonia, pleural effusions, respiratory failure, sepsis, surgical complications (such as anastomotic or wound dehiscence), and intra-abdominal infections.
CONCLUSION: The CRS and HIPEC technique is a major surgery with significant morbidity, as highlighted by the perioperative concerns observed in our study. Copyright: © Singapore Medical Association

Entities:  

Keywords:  anaesthesia; cytoreductive surgery; intraperitoneal chemotherapy

Mesh:

Year:  2016        PMID: 27121920      PMCID: PMC5563529          DOI: 10.11622/smedj.2016078

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   1.858


  15 in total

Review 1.  Thoracic epidural analgesia and acute pain management.

Authors:  Smith C Manion; Timothy J Brennan
Journal:  Anesthesiology       Date:  2011-07       Impact factor: 7.892

Review 2.  Bilateral thoracic paravertebral block: potential and practice.

Authors:  J Richardson; P A Lönnqvist; Z Naja
Journal:  Br J Anaesth       Date:  2011-02       Impact factor: 9.166

Review 3.  Systematic review of the Sugarbaker procedure for pseudomyxoma peritonei.

Authors:  J Bryant; A J Clegg; M K Sidhu; H Brodin; P Royle; P Davidson
Journal:  Br J Surg       Date:  2005-02       Impact factor: 6.939

Review 4.  Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy.

Authors:  A J Witkamp; E de Bree; R Van Goethem; F A Zoetmulder
Journal:  Cancer Treat Rev       Date:  2001-12       Impact factor: 12.111

Review 5.  Peritoneal-based malignancies and their treatment.

Authors:  Melissa Teo
Journal:  Ann Acad Med Singapore       Date:  2010-01       Impact factor: 2.473

6.  Peritonectomy procedures.

Authors:  P H Sugarbaker
Journal:  Ann Surg       Date:  1995-01       Impact factor: 12.969

7.  Early use of the pulmonary artery catheter and outcomes in patients with shock and acute respiratory distress syndrome: a randomized controlled trial.

Authors:  Christian Richard; Josiane Warszawski; Nadia Anguel; Nicolas Deye; Alain Combes; Didier Barnoud; Thierry Boulain; Yannick Lefort; Muriel Fartoukh; Frederic Baud; Alexandre Boyer; Laurent Brochard; Jean-Louis Teboul
Journal:  JAMA       Date:  2003-11-26       Impact factor: 56.272

8.  Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer.

Authors:  Rhonda L Harmon; Paul H Sugarbaker
Journal:  Int Semin Surg Oncol       Date:  2005-02-08

Review 9.  Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group.

Authors:  Rinaldo Bellomo; Claudio Ronco; John A Kellum; Ravindra L Mehta; Paul Palevsky
Journal:  Crit Care       Date:  2004-05-24       Impact factor: 9.097

10.  Anaesthesia in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: retrospective analysis of a single centre three-year experience.

Authors:  Marie-Elisabeth Kajdi; Beatrice Beck-Schimmer; Ulrike Held; Reto Kofmehl; Kuno Lehmann; Michael Thomas Ganter
Journal:  World J Surg Oncol       Date:  2014-05-01       Impact factor: 2.754

View more
  8 in total

1.  Anesthesia and Pain Management for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Desmoplastic Small Round Cell Tumors in Children, Adolescents, and Young Adults.

Authors:  Doralina L Anghelescu; Christina-Lin Brown; Andrew J Murphy; Andrew M Davidoff; Paxton V Dickson; Evan S Glazer; Zachary E Stiles; Michael W Bishop; Luke Douthitt; Jeremiah L Deneve
Journal:  Ann Surg Oncol       Date:  2018-10-23       Impact factor: 5.344

Review 2.  Analgesia for Gynecologic Oncologic Surgeries: A Narrative Review.

Authors:  Kaiwal Patel; Sukhman Shergill; Nalini Vadivelu; Kanishka Rajput
Journal:  Curr Pain Headache Rep       Date:  2022-02-03

3.  Increased Plasma Levels of Danger-Associated Molecular Patterns Are Associated With Immune Suppression and Postoperative Infections in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Authors:  Guus P Leijte; Hettie Custers; Jelle Gerretsen; Amon Heijne; Johannes Roth; Thomas Vogl; Gert J Scheffer; Peter Pickkers; Matthijs Kox
Journal:  Front Immunol       Date:  2018-04-05       Impact factor: 7.561

4.  Society of Onco-Anaesthesia and Perioperative Care consensus guidelines for perioperative management of patients for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC).

Authors:  Sohan Lal Solanki; Sudipta Mukherjee; Vandana Agarwal; Raghu S Thota; Kalpana Balakrishnan; Shagun Bhatia Shah; Neha Desai; Rakesh Garg; Reshma P Ambulkar; Nitin Madhukar Bhorkar; Viplab Patro; Snita Sinukumar; Meenakshi V Venketeswaran; Malini P Joshi; Rajesh Holalu Chikkalingegowda; Vijaya Gottumukkala; Pascal Owusu-Agyemang; Avanish P Saklani; Sanket Sharad Mehta; Ramakrishnan Ayloor Seshadri; John C Bell; Sushma Bhatnagar; Jigeeshu V Divatia
Journal:  Indian J Anaesth       Date:  2019-12-11

5.  Perioperative anaesthetic management in cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC): a retrospective analysis in a single tertiary care cancer centre.

Authors:  Raghav Gupta; Nishkarsh Gupta; Prashant Sirohiya; Anuja Pandit; Brajesh Kumar Ratre; Saurabh Vig; Swati Bhan; Ram Singh; Balbir Kumar; Shweta Bhopale; Seema Mishra; Rakesh Garg; Sachidanand Jee Bharati; Vinod Kumar; Suryanarayana Deo; Sushma Bhatnagar
Journal:  Pleura Peritoneum       Date:  2022-05-30

6.  Anaesthetic management and perioperative outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: A retrospective analysis.

Authors:  Kalpana P Balakrishnan; Sreedevi Survesan
Journal:  Indian J Anaesth       Date:  2018-03

Review 7.  Anesthetic implications in hyperthermic intraperitoneal chemotherapy.

Authors:  Nishkarsh Gupta; Vinod Kumar; Rakesh Garg; Sachidanand Jee Bharti; Seema Mishra; Sushma Bhatnagar
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2019 Jan-Mar

8.  Efficacy of fibrinogen concentrate in major abdominal surgery - A prospective, randomized, controlled study in cytoreductive surgery for pseudomyxoma peritonei.

Authors:  Ashok Roy; Sophia Stanford; Sean Nunn; Sue Alves; Nigel Sargant; Savita Rangarajan; Emily Arbuthnot Smith; John Bell; Sanjeev Dayal; Tom Cecil; Alexios Tzivanakis; Irina Kruzhkova; Cristina Solomon; Sigurd Knaub; Brendan Moran; Faheez Mohamed
Journal:  J Thromb Haemost       Date:  2019-11-26       Impact factor: 5.824

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.